Minhee Kang

Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy.

Nyirenda M, Ngongondo M, Kang M, Umbleja T, Krown SE, Godfrey C, Samaneka W, Mngqibisa R, Hoagland B, Mwelase N, Caruso S, Martinez-Maza O, Dittmer DP, Borok M, Hosseinipour MC, Campbell TB.

2020 Aug 01. 84(4):422-429. PMID: 32265361

Interim monitoring in a treatment strategy trial with a composite primary endpoint.

Kang M, Grund B, Hunsberger S, Glidden D, Volberding P.

Contemp Clin Trials. 2019 11. 86:105846. PMID: 31520741

PNPLA3 Gene Polymorphisms in HCV/HIV-Coinfected Individuals.

Sherman KE, Rouster SD, Kang M, Umbleja T, Sterling R, Butt AA.

Dig Dis Sci. 2018 11. 63(11):2969-2974. PMID: 30218427

Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1.

Cespedes MS, Kang M, Kojic EM, Umbleja T, Godfrey C, Webster-Cyriaque JY, Masih R, Firnhaber C, Grinsztejn B, Saah A, Cu-Uvin S, Aberg JA.

Papillomavirus Res. 2018 12. 6:15-21. PMID: 30118852

As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial.

Hosseinipour MC, Kang M, Krown SE, Bukuru A, Umbleja T, Martin JN, Orem J, Godfrey C, Hoagland B, Mwelase N, Langat D, Nyirenda M, MacRae J, Borok M, Samaneka W, Moses A, Mngqbisa R, Busakhala N, Martínez-Maza O, Ambinder R, Dittmer DP, Nokta M, Campbell TB.

Clin Infect Dis. 2018 07 02. 67(2):251-260. PMID: 29365083

Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).

Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG.

Open Forum Infect Dis. 2018 Jun. 5(6):ofy103. PMID: 29977962

Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.

Shive CL, Judge CJ, Clagett B, Kalayjian RC, Osborn M, Sherman KE, Fichtenbaum C, Gandhi RT, Kang M, Popkin DL, Sieg SF, Lederman MM, Rodriguez B, Anthony DD.

Vaccine. 2018 01 25. 36(4):453-460. PMID: 29254840

Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.

Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS.

Liver Int. 2018 06. 38(6):1010-1021. PMID: 29091342

Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection.

Sherman KE, Kang M, Sterling R, Umbleja T, Marks K, Kiser JJ, Alston-Smith B, Greaves W, Butt AA.

World J Hepatol. 2017 Feb 08. 9(4):217-223. PMID: 28217259

Brief Report: CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy.

Judge CJ, Sandberg JK, Funderburg NT, Sherman KE, Butt AA, Kang M, Landay AL, Lederman MM, Anthony DD.

2016 11 01. 73(3):258-262. PMID: 27258231